Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Serina Therapeutics
SER.US
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
1.880 T
SER.USMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking303/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE221.81%A
    • Profit Margin-16022.41%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-96.33%E
    • Net Profit YoY-155.82%E
    • Total Assets YoY66.95%A
    • Net Assets YoY111.53%A
  • Cash ScoreE
    • Cash Flow Margin-0.62%D
    • OCF YoY-96.33%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio87.16%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More